- Home
- / 4SC
4SC
Stock Price
€6
2024-10-29
Market Capitalization
€68.6 M
2024-10-29
Revenue
€336 K
FY, 2024
4SC Summary
Company Summary
- Overview
- 4SC is a biopharmaceutical company developing small-molecule drugs for the treatment of cancer. Its primary product, Resminostat, is an orally administered histone deacetylase (HDAC) inhibitor aimed at inhibiting tumor growth and metastasis.
- Type
- Public
- Status
- Active
- Founded
- 1997
- HQ
- Planegg, DE | view all locations
- Website
- https://www.4sc.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Kathleen Masch-Wiest, Chief Operating Officer (COO), Member of the Management Board
LocationsView all
1 location detected
Planegg, BY HQ
Germany
Fraunhoferstraße 22
4SC Financials
Summary Financials
- Revenue (H1, 2025)
- €39.0K
- Net income (H1, 2025)
- (€3.3M)
- Cash (H1, 2025)
- €5.4M
- EBIT (H1, 2025)
- (€3.2M)